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Abstract: An understanding of the risks, benefits, and relative value of glatiramer acetate (GA) 
in multiple sclerosis (MS) has been evolving based on recently completed head-to-head studies: 
REGARD (REbif vs Glatiramer Acetate in Relapsing MS Disease); BEYOND (Betaseron 
  Efficacy Yielding Outcomes of a New Dose); and BECOME (BEtaseron vs COpaxone in Multiple 
Sclerosis with Triple-Dose Gadolinium and 3-Tesla MRI Endpoints). Outcomes in the primary 
endpoints of these trials showed no significant differences between GA and high-dose beta-inter-
ferons (IFNβs). Results of the PreCISe (Early GA Treatment in Delaying Conversion to Clinically 
Definite Multiple Sclerosis [CDMS] in Subjects Presenting With a Clinically Isolated Syndrome 
[CIS]) trial led to the US Food and Drug Administration approval of GA in patients with a CIS. 
Furthermore, the ongoing follow-up study to the original pivotal GA trial, now extending beyond 
15 years, continues to support the safety of GA. Currently, GA and IFNβs are no longer the only 
immunomodulators available for MS. Introduction of the monoclonal antibody, natalizumab 
(Tysabri®; Biogen Idec, Inc., Cambridge, MA, USA) provides an alternative immunomodulator 
for MS and has changed the therapeutic landscape dramatically. However, the rare but serious 
cases of progressive multifocal leukoencephalopathy that have occurred with natalizumab have 
raised concerns among clinicians and patients about using this agent and some of the emerging 
agents. The potential risks and benefits of the emerging therapies (cladribine, alemtuzumab, 
rituximab, fingolimod, laquinimod, teriflunomide, and dimethyl fumarate) based on phase II/III 
trials, as well as their use for indications other than MS, will be presented. This review provides 
available data on GA, natalizumab, and the emerging agents to support new developments in 
our understanding of GA and how its long-standing role as a first-line therapy in MS will evolve 
within the increasingly complex MS therapeutic landscape.
Keywords: annual relapse rate, alemtuzumab, cladribine, rituximab, fingolimod, teriflunomide, 
dimethyl fumarate, laquinimod, interferon
Introduction
Glatiramer acetate (GA) (Copaxone®; Teva Neuroscience, Kansas City, MO, USA) 
has been available as a first-line therapy for relapsing-remitting multiple sclerosis 
(RRMS) since 1996. Our understanding of the therapeutic value of GA has evolved 
since then based on a number of important studies, which were recently reviewed by 
Johnson and Due.1 Until recently, GA and the beta-interferons (IFNβs) were the only 
immunomodulatory therapies available for treatment of RRMS; however, with the 
introduction of the monoclonal antibody, natalizumab (Tysabri®; Biogen Idec, Inc., 
Cambridge, MA, USA), the MS therapeutic landscape has changed dramatically. Many 
new considerations have contributed to therapeutic decisions being made in MS. In 
patients with continued disease activity despite treatment with disease-modifying Therapeutics and Clinical Risk Management 2010:6 154
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used in the future will depend not only on the risk-vs-benefit 
analysis of GA, but also on the risks and benefits of these 
emerging therapies. At the present time, our vision must be 
forward-looking rather than entirely evidence-based. This 
review will discuss the new developments in our understand-
ing of GA, and the role GA may play in this new, evolving, 
and complex therapeutic landscape in MS.
Glatiramer acetate
GA, a member of the glatiramoid class of compounds,7 is 
composed of a mixture of synthetic polypeptides derived 
from 4 amino acids that was originally designed to create 
a multiple peptide analog of myelin basic protein.8 It was 
synthesized in the 1960s and studied first in many animal 
models and then in human patients with RRMS over a 
period of 30 years, culminating in its approval in the United 
States in 1996.8 The mechanism of action (MOA) of GA is 
immunomodulatory. GA appears to modulate inflammation 
and act in a neuroprotective capacity (Figure 1).9 GA may 
shift T-lymphocyte populations in the systemic circulation 
via the induction of reactive Th2 immunoregulatory cells10 
that have been demonstrated in experimental autoimmune 
encephalomyelitis (EAE) models to cross into the central 
nervous system (CNS) to release antiinflammatory cytokines 
and growth factors.11 In addition, GA stimulates the secretion 
of neurotrophins that protect axons and may promote repair 
to damaged neurons.10
The safety and efficacy of GA have been demonstrated 
over many years, starting in 1995, with the findings provided 
by a pivotal, placebo-controlled trial,12 and more recently by 
head-to-head trials comparing GA with high-dose IFNβs. 
Also, prospective, follow-up studies of over a decade using 
GA as monotherapy have provided additional confirmation 
of safety.13
Head-to-head trials
Three head-to-head trials have been completed that compared 
the efficacy and safety of high-dose IFNs with GA. Although 
it is difficult to compare results across different studies due 
to the lack of a placebo arm, these 3 trials found that there 
were no significant differences between high-dose IFN-based 
therapies and GA in primary endpoints evaluating reductions 
in relapse rates.14–16
The REGARD (REbif vs Glatiramer Acetate in Relapsing 
MS Disease) study, a randomized, comparative, parallel-group, 
open-label trial, included 764 patients with RRMS (diagnosed 
by McDonald criteria) who had experienced at least 1 relapse 
in the past year. The subjects received either 44 µg of IFNβ-1a 
agents, natalizumab may be used as second-line therapy.2 
However, use of natalizumab has led to rare but serious cases 
of progressive multifocal leukoencephalopathy (PML). There 
are many concerns regarding natalizumab as new cases of 
PML and other infections continue to occur in association 
with its use.3 Recently, a 40-year-old male with RRMS 
developed a primary central nervous system lymphoma 
(PCNSL) following 21 doses of natalizumab monotherapy. 
Because this patient was not otherwise immunocompromised 
and there is no increased prevalence of PCNSL in MS, the 
association between natalizumab therapy and PCNSL was 
conceivable.4 These findings of rare opportunistic infections 
and malignancies have raised a cautionary note among 
  clinicians and patients who may be contemplating the use 
of this agent and other therapies that will be emerging in the 
near future. Also, recent reports show that the appearance of 
high-titered (1:100)5 neutralizing antibodies (NABs) totally 
blocks the biologic activity of IFNβs. The development of 
NABs6 may occur in up to 35% of IFNβ-treated patients, and 
this phenomenon may reduce or completely eliminate IFNβ 
bioactivity, depending upon the level of titers present.2 This 
information is changing treatment alternatives, especially in 
cases of suboptimal response.2 
With the emergence of multiple novel therapies currently 
in development, the MS therapeutic landscape is about to 
undergo more significant changes. Although some of these 
agents could be more efficacious than existing therapies (at 
least in the short term), risk-vs-benefit analyses must also take 
into account long-term safety and tolerability. Based on their 
use in clinical trials and experiences in therapeutic areas out-
side of MS, there is evidence that use of some of these emerg-
ing therapies may pose risks of developing opportunistic and 
community-acquired infections, malignancies, autoimmune 
disorders,3 and complications affecting body systems other 
than the neurologic system. They may, therefore, require ongo-
ing complex monitoring. The scope, as well as the duration of 
these effects, may not be completely predictable, complicating 
attempts to make reasonable and safe therapeutic decisions 
for MS patients.
With the current use of natalizumab and future use of 
several novel therapies, risk-vs-benefit analyses promise to be 
very different from what therapists faced when first-line MS 
regimens included solely GA and IFNs. The field of MS ther-
apy is changing, and until the phase III results of trials for the 
emerging therapies are available, and the US Food and Drug 
Administration makes a decision regarding the approval of 
these novel agents, it will be difficult to determine their role in 
the armamentarium of MS. Understanding of how GA will be Therapeutics and Clinical Risk Management 2010:6 155
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subcutaneous (SC) (Rebif®; EMD Serono, Rockland, MA, 
USA and Pfizer, Inc., New York, NY, USA) 3 times a week or 
20 mg of GA SC once a day for 96 weeks – 65 patients dis-
continued IFN and 49 patients discontinued GA, with 82% of 
764 patients completing the trial. Time to first relapse (primary 
  outcome) and magnetic resonance imaging (MRI) benchmarks 
(T2-weighted and gadolinium-enhancing [GdE] lesion number 
and brain volume) were studied. After 96 weeks, there was no 
significant difference between groups in the time to first relapse 
(Figure 2) (hazard ratio [HR] 0.94, 95% confidence interval 
[CI], 0.74–1.21; P = 0.64), and both groups had lower than 
predicted relapse rates.14
Annualized relapse rates (ARRs) were not different 
between the groups (Figure 3A). In terms of MRI outcomes, 
there were no significant differences in the number and 
change in volume of T2 active lesions. Patients treated 
with IFNβ-1a SC had significantly fewer GdE lesions 
(0.24 vs 0.41 lesions per patient per scan; P = 0.0002) and 
patients treated with GA experienced significantly less brain 
atrophy (P = 0.018).14
The BEYOND (Betaseron Efficacy Yielding Outcomes of 
a New Dose) study compared 3 treatment groups (N = 2244 in 
a 2:2:1 randomization): 250 µg of IFNβ-1b SC (Betaseron®, 
Bayer HealthCare Pharmaceuticals, Montville, NJ, USA) 
dosed every other day; IFNβ-1b 500 µg SC dosed every other 
day; GA 20 mg SC daily over 2 years.15 The primary endpoint 
for this study was the risk of relapses; however, the study also 
examined the time to confirmed Expanded Disability Status 
Scale (EDSS) progression and MRI parameters. Annualized 
relapse rates were 0.33, 0.36, and 0.34 for IFNβ-1b 500 µg, 
IFNβ-1b 250 µg, and GA, respectively, and did not differ 
(Figure 3B). No significant differences were found in time 
to first relapse, overall relapse rates during the study period, 
and proportion of patients who remained relapse free.15 For 
MRI data, there was no significant difference in GdE lesions, 
T1 lesions, and normalized brain volume.
There were significant differences in the cumulative 
  number of new T2 lesions between the 3.3 lesions in 
patients on IFNβ-1b 500 µg and the 3.3 lesions in patients 
on IFNβ-1b 250 µg compared with the 4.6 lesions in patients 
treated with GA (P = 0.0009 and P = 0.011, respectively). T2 
lesion volume increased for all 3 treatment groups: IFNβ-1b 
500 µg, IFNβ-1b 250 µg, and GA 20 mg, by 12%, 10%, and 
17%, respectively, with a significant difference between GA 
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Figure 1 Mechanisms of action of glatiramer acetate (GA) in MS. 
Reprinted from Autoimmun Rev, Vol. 6, Schrempf W, Ziemssen T, Glatiramer acetate: mechanisms of action in multiple sclerosis, 469–475.9 Copyright © 2007, with permission 
from Elsevier. 1. GA exhibits competitive binding at the MHC-II complex and TCRantagonism. In addition, GA is able to displace MBP from the binding site on MHC-II molecules. 
Treatment with GA leads to the induction of antigen specific TH2 T cells in the periphery. 2. In addition CD8+ and CD4+ CD25+ regulatory T cells are induced by GA therapy. 
3. The constant activation seems to have an important impact on the induction and maintenance of the regulatory/suppressive immune cells. 4. Because of the daily activation, 
GA T cells are believed to be able to cross the blood–brain barrier. 5. Inside the CNS, some GA-specific T cells cross-react with products of local myelin turnover presented 
by local APCs. 6. In response anti-inflammatory cytokines are secreted which dampen the local inflammatory process (bystander suppression). 7. Furthermore GA specific T 
cells secrete neurotrophic factors which might favor remyelination and axonal protection.
Abbreviations:  APC, antigen-presenting cells; MHC, major histocompatibility complex; TCR, T cell receptor.Therapeutics and Clinical Risk Management 2010:6 156
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and the high and low IFN doses, P = 0.0008 and P = 0.0001, 
respectively.15 Among 2244 patients, 1934 (86%) completed 
the study. The highest number of dropouts (161 patients) was 
observed among those patients receiving IFNβ-1b 500 µg, 
followed by patients receiving IFNβ-1b 250 µg (104 patients), 
with 71 patients receiving GA dropping out.
The BECOME (BEtaseron vs COpaxone in Multiple 
Sclerosis with Triple-Dose Gadolinium and 3-Tesla MRI 
Endpoints) study was a head-to-head study conducted to 
determine the efficacy of treatment with IFNβ-1b or GA 
as assessed by monthly brain MRI.16 A total of 75 patients 
with RRMS or clinically isolated syndrome (CIS) were 
enrolled in the study; 4 patients in each group discontinued 
the study medication. They were randomized to receive 
either IFNβ-1b 250 µg SC every other day or GA 20 mg SC 
daily and underwent enhanced MRI scans for up to 2 years. 
Investigators used a specialized protocol with triple-dose Gd 
and delayed imaging post-injection, utilizing a 3-Tesla MRI 
scanner – all of which were intended to maximize detection 
of combined active lesions (CALs; CAL refers to the total 
number of contrast-enhancing lesions plus new nonenhancing 
lesions on long repetition time scans that have appeared since 
the most recent examination).16 There were similar median 
(75th percentile) CALs per patient per scan for Months 1 to 
12 – 0.63 (2.76) for IFNβ-1b and 0.58 (2.45) for GA. In 
addition, there were no significant differences in the effects 
of the medications on relapse rates. The ARR for IFNβ-1b 
changed from 1.8 to 0.37, with a reduction of 79% com-
pared with a difference of 1.9 to 0.33 for GA, representing 
an 83% reduction in ARR from baseline with treatment for 
each agent, respectively.16
When examining the data from these 3 head-to-head 
trials, it is important to note that GA performed similarly 
to the high-dose IFN-based therapies in efficacy on the pri-
mary endpoints, including relapse rate reductions and onset 
of action. Overall, reductions in relapse rates were much 
greater in each of these head-to-head trials than those reported 
during the pivotal trial for GA in 1995.12 Furthermore, the 
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Figure 2 REGARD trial: Kaplan–Meier plot of time to first relapse.14 
Reprinted with permission from Mikol DD, Barkhof F, Chang P, et al. Compari-
son of subcutaneous interferon beta-1a with glatiramer acetate in patients with 
  relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease 
[REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 
2008;7(10):903–914.14 Copyright © 2009, with permission from Elsevier.
Abbreviations: GA, glatiramer acetate; HR, hazard ratio; IFN, interferon; REGARD, 
REbif vs Glatiramer Acetate in Relapsing MS Disease.
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DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in 
Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7(10):903–914.14 Copyright © 2009, with permission from Elsevier.
Abbreviations: ARR, annual relapse rate; REGARD, REbif vs Glatiramer Acetate in Relapsing MS Disease; BEYOND, Betaseron Efficacy Yielding Outcomes of a New Dose.Therapeutics and Clinical Risk Management 2010:6 157
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ARR achieved with GA (range, 0.29 to 0.34)14–16 was much 
improved compared with that achieved in the pivotal trial 
(0.59).12 In the pivotal trial, there was a 29% reduction in 
favor of GA over placebo (P = 0.007), with an ARR of 
0.59 for GA and 0.84 for placebo.12 A difference in patient 
populations was the most likely explanation for this trend. 
Currently, earlier diagnosis of MS and earlier treatment 
  initiation are possible through the use of imaging-based 
McDonald criteria rather than clinically based criteria, and 
the patient populations of these trials reflect this shift. Results 
from the more recent trials14–16 are probably more indicative 
of the effectiveness that should be expected with initiation 
of GA therapy in a newly diagnosed RRMS patient who is 
more likely to resemble patients in these newer studies rather 
than those in the pivotal trial.12
Indication for CIS
The PreCISe (Early GA Treatment in Delaying Conversion 
to Clinically Definite Multiple Sclerosis [CDMS] in Subjects 
Presenting With a Clinically Isolated Syndrome [CIS]) trial 
evaluated the effect of GA on delaying conversion of patients 
with CIS to CDMS. Data from this trial, including results that 
showed GA delays conversion of CIS to CDMS, led to the 
recent US Food and Drug Administration (FDA) approval of 
the use of GA for the treatment of patients with CIS.17 The 
primary endpoint of the study was the time to CDMS. A total 
of 481 patients who had experienced a single,  unifocal, clinical 
attack participated in the study. Those in the active treatment 
arm received GA 20 mg SC per day. The Drug Monitoring 
Committee (DMC) conducted an interim analysis (mean 
exposure was 2.3 [SD 0.65] years, 81% of the targeted 3-year 
study) and based on the results, the DMC recommended the 
placebo arm of the trial be stopped, and all placebo patients 
be given the opportunity to receive active treatment with 
GA for 2 years.17 The trial data demonstrated that there was 
a significant delay of 386 days in conversion to CDMS: 
722 days for the GA-treated group compared with 336 days 
for the untreated patients (HR = 0.55, 95% CI, 0.40–0.77; 
P = 0.0005) (Figure 4). Patients who converted to CDMS then 
continued on active treatment for an additional 2 years.17
During the PreCISe trial, it was noted that GA also had 
an impact on MRI and magnetic resonance spectroscopy 
(MRS) parameters.18,19 Specifically, patients receiving GA 
experienced a 58% reduction in new T2-weighted lesions 
(P  0.0001) and exposure-adjusted T2-weighted lesion 
volume (P = 0.0002).18 GA also reduced the number of new 
T1 GdE and new T1 hypointense lesions (P = 0.0001).18 In 
addition, evidence exists for axonal protection with use of 
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Figure 4 Time to conversion to CDMS in the placebo-controlled phase. Kaplan–Meier 
curves with Cox’s proportional hazard ratio were used to model the amount of time 
to conversion to CDMS for patients assigned to GA and placebo. A delay of 386 days 
(115%) in conversion to CDMS was noted for first quartile of patients receiving 
GA compared with those receiving placebo. Reprinted from The Lancet, Comi G, 
Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically 
definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): 
a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1503–1511.17 
Copyright 2009, with permission from Elsevier.
Abbreviations: CDMS, clinically definite multiple sclerosis; GA, glatiramer acetate.
GA in patients with CIS. MRS techniques demonstrated a 
significant difference in paired changes of N-acetylaspartate 
(NAA)/creatine ratios between patients treated with GA 
vs those treated with placebo, which remained for up to 
24 months.19 Finally, GA was well tolerated among the 
patients with CIS, with a side-effect profile similar to that 
seen in patients treated with GA for RRMS.17
Long-term data
Despite the chronic nature of MS and the growing trend to 
recommend initiation of disease-modifying therapies (DMTs) 
early in the disease course (eg, upon diagnosis of CIS), there 
are scant data on the efficacy and safety of DMTs beyond 
5 years. Ford et al13 conducted a prospective, open-label, 
extension study to evaluate the neurologic status and EDSS 
scores in patients from the original pivotal trial of GA12 who 
had used GA for up to 15 years.13 As of November 2003, 
108 (47%) patients from the 232 originally enrolled in the 
US Glatiramer Acetate Pivotal Trial who had taken GA for 
an average of 10 years remained in the open-label extension 
phase. Of the 124 who withdrew from the study, 50 were 
available for long-term follow-up (LTFU) and 74 were not, 
resulting in a total of 158 (68%) patients from the original 
study who were evaluable at 10 years.13 Investigators found 
that while on GA, relapse rates declined from 1.18 per year 
pre-study to approximately 1 relapse every 5 years – a decline Therapeutics and Clinical Risk Management 2010:6 158
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of 80%.13 The median time to 1-point increase in EDSS 
score was 8.8 years; 58% of patients had stable or improved 
EDSS scores,13 while 38%,18%, and 3% reached EDSS scores 
of 4, 6, and 8, respectively (among patients who had received at 
least 1 GA dose since study inception).20 While receiving GA, 
nearly all patients (with a mean disease duration of 15 years) 
were ambulatory, with EDSS scores of 6.13 A LTFU visit 
of patients who had withdrawn from the pivotal trial showed 
that these patients had greater disability than patients who 
had continued on GA, with slightly higher EDSS scores 
(3.00 ± 1.59 [SD] vs 2.569 ± 1.35, respectively; P = 0.03).13
The safety profile of GA was favorable over the long 
term, with the most common adverse events (AEs) related 
to GA use being local injection-site reactions (erythema, 
pain, mass, edema) and self-limited immediate post-injection 
reactions. No other immune-mediated disorders, infections, 
or malignancies have been associated with long-term use of 
GA.13 The mean duration of GA treatment was 4.269 ± 3.13 
[SD] years (range: 0.2–11.5) in the Withdrawn Total cohort. 
The GA exposure was 4.479 ± 2.95 years (range: 0.2–10.4) 
in the Withdrawn with LTFU cohort, and 4.139 ± 3.26 years 
(range: 0.2–11.5) in the Withdrawn without LTFU cohort, and 
there were no statistical differences in demographic or disease 
  characteristics between withdrawn patients who returned for 
LTFU and withdrawn patients who did not return at the time 
of GA initiation. Because no objective neurologic evaluations 
were conducted on the patients at the time they withdrew, 
subjective data about patients who withdrew from the study 
due to their own perception that their disease was worsening 
cannot be supported by objective data. In addition, patients 
who withdrew from this study did so for various reasons, 
not only based on the perception of worsening disease. For 
example, patients withdrew for non-MS-related issues, such 
as lack of transportation to the study site or pregnancy.13
Suboptimal responses to DMTs
The relative frequency of suboptimal responses to MS therapy 
has been noted to be as high as 30% in 3 years post-initiation 
of first-line therapies.21 Criteria for defining what constitutes 
a suboptimal response vary, however. Typical criteria include 
relapse rates greater than 1 per year or unchanged from 
pretreatment rates; incomplete recovery from relapses; new 
brainstem or spinal cord lesions; or progression of disability 
or cognitive impairment that leads to a disruption in activities 
of daily living.22 A significant cause of suboptimal response 
in the case of IFN therapy is the development of NABs (this 
has been recently reviewed by Rudick and Polman).2 Reports 
indicate how NABs reduce or abolish IFNβ bioactivity in a 
titer-dependent manner.2,23 The appearance of high-titered 
(1:100)5 NABs has been shown to block the biologic activity 
of IFNβs. NABs may occur in up to 35% of IFNβ-treated 
patients, with several studies suggesting that IFNβ-1b is most 
immunogenic (35% of patients NAB-positive) followed by 
subcutaneous IFNβ-1a (23.7% of patients NAB-positive) and 
lastly intramuscular IFNβ-1a (7% of patients NAB-positive), 
as indicated in one review by Rudick.2
Another potential cause of suboptimal responses to 
DMTs is a lack of adherence to therapies over the long 
term, because 4 of 6 currently available therapies require 
self-injection, and all have side effects that may range 
from influenza-like symptoms to injection-site reactions. 
  Barriers to adherence thus include needle phobia and coping 
with the aforementioned AEs as well as others, but also 
include additional issues, such as not taking medication 
because of forgetfulness, complacency, treatment fatigue, 
changes in socioeconomic circumstances, and perceived 
lack of efficacy.24 Specifically related to GA, a study by 
Haas and Firzlaff of 308 patients with RRMS conducted 
over 24 months indicated a significantly (P  0.001) lower 
discontinuation rate for GA compared with the 3 IFN-based 
therapies.25 However, regardless of whether patients are 
treated with IFNβ or GA, adherence rates for 2 to 5 years 
range from 60% to 76% overall,24 and 49% discontinue 
treatment within the first 2 years.25 Adverse events that most 
commonly resulted in treatment discontinuation (affecting 
approximately 5% of 563 patients) for GA during the clini-
cal trials included injection-site reactions, dyspnea, urticaria, 
vasodilatation, and hypersensitivity.26 The most common 
adverse reactions overall were: injection-site reactions, 
vasodilatation, rash, dyspnea, and chest pain.24,26 Localized 
lipoatrophy is another AE that may lead to nonadherence. 
This occurred in approximately 2% of patients participating 
in the clinical trials.26 Evidence suggests that healthcare pro-
viders can have an impact on patient adherence by assuring 
a close relationship with their patients, providing education 
and support, reinforcing the need to continue treatment, and 
managing treatment expectations, as well as side effects.24
Although there is minimal class I or class II evidence on 
the impact of switching DMTs to improve patient response 
or eliminate AEs, 3 open-label studies have been conducted 
to investigate whether changing from an IFN-based therapy 
to GA improves outcomes in patients who have experienced 
suboptimal responses to IFNs.27–29
Caon et al27 evaluated the clinical course of 85 patients 
with RRMS who had received weekly doses of IFNβ-1a 
intramuscular (IM) (Avonex®, Biogen, Inc, Cambridge, Therapeutics and Clinical Risk Management 2010:6 159
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MA, USA) for 18 months, but who were switched to GA 
therapy due to either persistent suboptimal efficacy (n = 62) 
or persistently unacceptable toxicity (n = 23).27 Treatment 
with IFNβ-1a IM reduced the ARR from 1.41 to 1.23 after a 
mean duration of 19.7 months. In the patients with a persistent 
suboptimal efficacy who were switched to GA, the mean 
ARR was reduced from 1.32 to 0.52 (P = 0.0001).27 GA 
therapy was effective in a group of patients who switched 
due to persistent toxicity associated with IFN therapy. 
Within this group, therapeutic efficacy was maintained after 
the switch to GA: the ARR decreased slightly from 0.61 to 
0.47.27 In addition, in each group, EDSS scores improved by 
approximately 0.5 points in each group after the switch to 
GA.27 There were 5 (8%) patients who, due to suboptimal 
efficacy, were switched to GA, but failed to respond to this 
therapy as well. Two patients who had been switched to GA 
due to intolerable toxicity from IFNβ-1a IM also did not 
demonstrate a reduction in ARR. Excluding these patients 
from the analysis, however, did not affect the results. Six 
patients were lost to follow-up, and no data are available 
on whether patients taking GA subsequently discontinued 
this therapy.27
Similarly, Carrá et al28 found that switching to GA 
  following IFN therapy improved effectiveness and stabilized 
disability progression when there had been a suboptimal 
response to IFN therapy. This was a prospective longitudinal 
observational study of 114 patients with RRMS who 
switched treatments after 3 years. Patients were switched 
either from low-dose to high-dose IFNβ (n = 31), from 
IFNβ to GA (n = 52) or mitoxantrone (n = 13), or from GA 
to IFNβ (n = 16).28 Patients who had failed treatment were 
candidates for a switch in therapies. Criteria for treatment 
failure included either inadequate efficacy or the occurrence 
of AEs. In the case of the treatment group of 18 patients 
originally treated with GA, 14 (77.8%) were switched due to 
inadequate efficacy. In the group of patients switched from 
IFNβ to GA, the ARR was reduced from 0.63 to 0.14, a 
decrease of 77%, with 68% of those who had been switched 
due to efficacy concerns not experiencing a relapse over the 
entire treatment period of 3 years (an improvement from 
16% who were relapse free in the period before the switch 
to GA).28 Furthermore, patients who switched from IFNβ to 
either GA or mitoxantrone did not experience a significant 
progression in their EDSS scores. This was in contrast to 
patients who switched from low-dose IFN-based therapy to 
a high-dose IFN-based therapy and continued to increase 
their disability scores.28 All groups (IFNβ to GA, low-dose 
IFNβ to high-dose IFNβ, IFNβ to mitoxantrone, and GA to 
IFNβ) in this study benefited from switching therapies.28 The 
best outcomes, as reflected by improvements in ARR and 
stabilization of EDSS scores, were in those patients switching 
to GA or mitoxantrone.28
A third study, by Zwibel29 compared clinical outcomes 
between 558 treatment-naive patients initiating treatment 
with GA and 247 patients who were switched from IFNβ-1b 
SC primarily due to occurrence of AEs, such as flu-like 
symptoms or injection-site reactions (36% stopped treatment 
with IFNβ-1b due to perceived lack of efficacy).29 Patients in 
the switch group were older and demonstrated more advanced 
disease, with higher baseline EDSS scores.29 For example, 
22% of those previously treated with IFNβ-1b had an EDSS 
score of 6.0% vs 10% of treatment-naïve patients. Following 
a switch, mean ARR in the switched patients decreased by 
75%, which was the same decrease noted in treatment-naive 
patients initially treated with GA.29 A total of 107 patients 
who had previously been on IFNβ-1b and 247 patients in 
the previously treatment-naive group discontinued GA 
before study completion. Both groups cited similar reasons 
for discontinuing GA – most commonly “patient decision” 
([n = 147; 18.3%], which was not further explained in the 
study), followed by “adverse experience” (n = 88; 10.9% of 
each cohort). Of the latter group, 30 patients discontinued 
due to an injection-site reaction; however, more than 97% 
of injection-site reactions overall were rated as mild or 
moderate in severity.29
In summary, these studies clearly demonstrate improve-
ments in ARRs and disability (as reflected by EDSS scores) 
when patients are switched from an IFN to GA.
Effect of GA on fatigue, depression,  
and work absenteeism
Although most commonly regarded as a progressive 
  neurologic disease that causes physical disability, MS is also 
associated with psychological symptoms that affect quality 
of life.30 These include fatigue and depression, which have 
an effect on such key functions as work performance.31 
Fatigue is highly prevalent among patients with MS,31,32 
reported by approximately 75% of patients33,34 and noted to 
be “one of the most distressing symptoms” of MS by 50% 
of patients.32,33 As a result, fatigue has a major impact on 
productivity. Among individuals with MS forced to work part-
time, 90% reported fatigue as the cause.31,35 Zeimssen et al33 
conducted a prospective, observational, noninterventional 
study of patients with RRMS (by McDonald criteria) to 
determine the impact of initiating GA treatment on fatigue 
and absenteeism. All patients were diagnosed with RRMS Therapeutics and Clinical Risk Management 2010:6 160
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(n = 291), treatment naive, and evaluated every 3 months 
for 1 year with neurologic assessments. Patients also were 
assessed for disability with EDSS; fatigue was assessed by a 
visual analog scale (VAS) and the Modified Fatigue Impact 
Scale (MFIS).33
Use of GA resulted in a significant reduction in fatigue 
and lost work days. MFIS scores decreased by 7.6 ± 16.4 
from 34.6 to 27.0 (P  0.001) and fatigue symptoms using 
a VAS decreased by 1.04 ± 2.88 cm from 4.47 cm to 3.43 cm 
(P  0.001). The proportion of patients absent from work 
at least once was reduced by a factor of 2 from 65.1% to 
30.1% (P  0.001). These reductions in fatigue and absen-
teeism corresponded with improvements in disability and 
relapses. The mean EDSS score at the end of treatment was 
2.45, representing a mean, statistically significant decrease 
from baseline of 0.55 points (P  0.05; Wilcoxon rank test). 
Furthermore, GA was found to be well tolerated. AEs, most 
frequently local injection-site reactions, were reported in 
15.1% of patients.33
While the pathogenesis of fatigue in MS is not clearly 
understood, it is thought to be either a nonspecific outcome 
of overall disease improvement or due to an impact of 
  treatment on the pathophysiology of MS fatigue.33 High 
levels of proinflammatory cytokines, for example, have been 
associated with exacerbation of fatigue.36 Therefore, the 
reduction in fatigue associated with GA may be due to the 
drug’s attenuation of secretion and activity of these cytokines 
within the CNS.37
Likewise, depression has been identified by several 
  studies to be prevalent among patients with MS.30 For 
example, a Canadian Community Health Survey found that 
the 12-month prevalence of major depression in patients with 
MS was 15.7% compared with 4.0% of patients without a 
chronic illness, but was also higher vs individuals with other 
chronic conditions in whom prevalence of depression was 
9.1%.30,38 MS patients experience approximately a 50% risk 
of major depression over their lifetime,39 and about 25% have 
suicidal ideation.30,40
GA does not appear to exacerbate depression, and may 
stimulate production of brain-derived neurotrophic factor 
(BDNF) that may have a positive effect on depression.30,41–43 
Depression has been associated with decreased levels of 
BDNF as well as with an inflammatory process in the brain.41 
Studies have demonstrated that GA administration can 
enhance central BDNF activity or increase serum BDNF lev-
els. When administered to animals, GA also has a central anti-
inflammatory effect through the release of interleukin-10.41 
Finally, peripheral administration of GA has been found to 
augment neurogenesis in rodents.41 Therefore, evidence from 
preclinical and clinical studies indicates that GA could have 
antidepressant effects by increasing central BDNF, decreas-
ing inflammation, and stimulating neurogenesis.41
Compounds related to currently 
approved GA
Other related compounds – of higher molecular weight (MW) 
and of higher dosage than currently approved GA – have also 
been explored for the treatment of MS. Like GA, protiramer 
is a glatiramoid but with a higher MW.7 Preliminary data 
from 2 pilot studies in patients with RRMS (n = 62 for 
both studies) showed that protiramer, 15 mg/week, had no 
  significant effect in reducing GdE lesions, while 30 mg/week 
significantly reduced the mean number of GdE lesions and 
new T2 W lesions (P = 0.0013 and P = 0.002, respectively) 
during a 36-week treatment phase.7 However, animal 
studies involving chronic use of protiramer (3 months) 
subsequently demonstrated serious toxicities that have not 
been shown with GA. For example, severe injection-site 
reactions (including disseminated necrosis and inflammation 
of dermal muscles, nerves, and blood vessels) in addition 
to kidney and liver lesions were observed in monkeys and 
rats.44 Furthermore, alterations in a number of hematologic 
and chemistry parameters were noted, and 2 deaths occurred 
in the group of monkeys being treated with high-dose 
  protiramer for 24 weeks.44 As a result, further development 
of protiramer has not been pursued.44
A phase II study to evaluate the safety, efficacy, and 
tolerability of GA at 40 mg/day (n = 46) vs the approved 
20 mg/day (n = 44) in patients with RRMS showed that 
the decrease in mean GdE lesions was significantly greater 
with the 40-mg dose vs the 20-mg dose (65% vs 75%, 
respectively [P  0.0001]). Furthermore, the higher dose 
was found to be safe and well tolerated, although some 
aspects of the injection-site reactions (eg, pain) were more 
common in the higher dose group.45 However, results from 
a phase III randomized, double-blind, parallel-group study 
to evaluate the safety, tolerability, and efficacy of GA 40 mg 
compared with 20 mg showed that the current dose of 20 mg 
and the higher dose of 40 mg were equally effective in 
reducing clinical relapses and MRI activity.46 In this study, 
1155 patients with definite MS (revised McDonald criteria) 
and at least one documented relapse in the 12 months prior to 
  screening, or at least 2 documented relapses in the 24 months 
prior to screening, and EDSS score 0–5.5, were enrolled. The 
primary endpoint was the rate of confirmed relapses. The 
patients were randomized to GA 20 mg (n = 586) or 40 mg Therapeutics and Clinical Risk Management 2010:6 161
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(n = 569). The primary efficacy endpoint was similar in both 
groups (relative risk = 1.07, P = 0.4859) with mean ARR of 
0.33 for the 20 mg and 0.35 for the 40 mg group, and 0.27 
for those who completed 1 year of treatment (ARR in the 
last year prior to study was 1.498). Among both groups, 77% 
were relapse free, and both demonstrated a reduction in GdE 
lesions and new T2 lesions.46
Summarizing recent developments  
with use of GA
Data now support the use of GA in a continuum of therapy 
from initiation of first-line therapy upon diagnosis with 
CIS17 or RRMS through its long-term use in patients with 
RRMS. Results from head-to-head trials with IFN therapies 
demonstrate similar potency and speed of onset for the first 
1 to 2 years after initiating therapy.14–16 In addition, ARR 
reductions with use of GA in numerous recent trials14–16 are 
much greater than those seen in its pivotal trial.12 The 70% to 
83% reduction in relapse rates (from that prior to initiating 
therapy) observed during these recent investigations 14–16 is 
probably much more indicative of the results that should 
be expected when initiating treatment with an early RRMS 
patient today. These reductions in ARRs are similar to 
those found with use of natalizumab in the AFFIRM 
(Natalizumab Safety and Efficacy in Relapsing Remitting 
Multiple Sclerosis) trial.47 Furthermore, the use of GA in 
cases of suboptimal response to IFNs appears in most cases 
to improve effectiveness.27–29
With regard to risks, long-term data (up to 15 years),13 
from the head-to-head trials,14–16 and data from the PreCISe 
trial17 indicate that GA is generally safe. Opportunistic 
  infections, malignancies, and the development of autoimmune 
diseases are not risks associated with GA, although tolerabil-
ity problems, especially related to injections and injection-site 
reactions (including lipoatrophy), continue to be an issue.13 
These new findings – particularly those that reflect on its 
long-term safety, its use earlier in the disease, and a better 
understanding of its efficacy relative to high-dose IFNs, 
and its effectiveness in patients after stopping IFNs – are 
  reshaping the risk-vs-benefit analysis for GA.
In an ever-evolving therapeutic landscape that will 
  probably include several additions in the near future, GA 
will remain a viable option for patients and clinicians given 
these new data indicating its continued safety, even after years 
of use, along with efficacy comparable to other currently 
  available therapies. Still, the future role of GA in MS therapy 
is dependent not only on the analysis of its own minor risks 
and considerable benefits, but also on the analysis of the 
risks and benefits associated with the emerging therapies 
for MS. Use will depend on the continuing risk-vs-benefit 
analysis of other drugs and, in the future, this will consist 
of multiple drugs currently under consideration, including 
those adapted based on use in other diseases; novel biologic 
agents; and – most eagerly anticipated by patients – the first 
oral therapies to be developed for the treatment of MS.
Risks and benefits  
of emerging therapies
Numerous new agents are in the final stages of development, 
particularly for the management of RRMS, and there is 
strong demand for oral therapies. With many of these agents, 
  balancing the risks and benefits will be difficult. Robust 
  preliminary efficacy data from initial clinical trials will 
have to be viewed against a backdrop of serious risks 
observed during the clinical trials; the protracted effects 
of some of these agents; and the limited data available, 
  particularly long-term data. Several of the novel therapies 
are being developed by adapting oncology products, such as 
  alemtuzumab (Campath®; Berlex Laboratories, Richmond, 
CA, USA), cladribine (Leustatin®; Ortho Biotech Products, 
Raritan, NJ, USA), and rituximab (Rituxan®; Genentech, 
Inc, South San Francisco, CA, USA), or those originally 
targeted for use in patients undergoing transplantation 
  (fingolimod). However, the risk-vs-benefit considerations 
are very different in these therapeutic areas compared with 
those for MS. Much more risk may be acceptable when 
  treating cancers and suppressing transplanted organ rejection. 
In these cases, the immediate morbidity and mortality are 
generally greater and the evaluations are made over the short 
term. In contrast, MS is a chronic, severely disabling, but 
not generally fatal disease, lasting decades. Also, MS often 
follows an unpredictable and clinically variable course. In 
this scenario, patients may be eager to prevent or minimize 
physical and cognitive disability; however, they may risk 
undergoing treatment with an agent for which a fairly 
complete understanding of its risks and benefits may not be 
available for several years, or even a decade or longer.
Several of the novel therapies alter host immune responses 
in a variety of ways and have strong immunosuppressive prop-
erties. Immunosuppressive therapies have been used much 
more extensively for treatment of conditions, such as in organ 
transplantation and for many neoplasms. Experience derived 
from use in transplantation reveals that the major long-term 
toxicities limiting the use of immunosuppressive regimens are 
opportunistic infections and malignancies.48 With the oppor-
tunistic infections observed with use of natalizumab,3 along Therapeutics and Clinical Risk Management 2010:6 162
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with opportunistic infections and malignancies observed 
in several of the recently completed trials with use of some 
of the emerging agents,49,50 these same concerns are now 
becoming part of the challenges associated with managing 
MS.48,51 Patients undergoing transplantation and the physi-
cians providing their care face a continually moving target 
as they provide antimicrobial prophylaxis for known threats, 
such as Pneumocystis ﾭcarinii and cytomegalovirus (CMV) 
wherein a new organism emerges, causing a new host of chal-
lenges.48,51 The same or similar issues may be a concern with 
the use of these immunosuppressive agents in MS.
The risks and benefits of 6 agents that are currently in 
or have just completed phase III trials will be discussed, 
including cladribine, alemtuzumab, rituximab, fingolimod, 
laquinimod, and dimethyl fumarate. The risks and benefits 
of the B-cell-targeted monoclonal antibodies, rituximab, and 
its humanized form, ocrelizumab, will be discussed due to 
the off-label use of rituximab.
Oncology agents in development  
for the treatment of MS
Cladribine
Cladribine was developed as a selective lymphocytotoxic agent 
for the treatment of lymphoid malignancies, including hairy-cell 
leukemia,52 and is being investigated for treatment of chronic lym-
phocytic leukemia (CLL)53,54 and acute myelogenous leukemia.55 
It is a purine nucleoside analog that is converted intracellularly 
to its active nucleotides in cells with a high level of deoxycyti-
dine kinase (phosphorylating enzyme) and low 5′-nucleotidase 
(dephosphorylating enzyme) activity.52 The active nucleotides 
interrupt cellular purine metabolism, damage DNA (cause 
double-strand DNA breaks), and ultimately lead to cell death.56 
Lymphocytes have a high ratio of deoxycytidine kinase to 
5′-nucleotidase, and resting and proliferating lymphocytes are 
selectively killed by cladribine.57 Some T-cell classes are depleted 
for more than 1 year by a single weekly cycle of cladribine 
treatment, and may affect several other immune cell types for 
4 to 12 months, an indication of the long duration of its actions.58 
Myelosuppression is the principal cause of toxicity, with life-
threatening infections as an immunosuppressive complication 
of cladribine therapy for cancer.59
Initial attempts at developing cladribine for the treatment 
of MS utilized parenteral formulations and involved 
6 different trials (reviewed by Leist and Vermersch).60 
Rice et al61 conducted a randomized, placebo-controlled 
trial of 159 patients with progressive MS and with 6.0 
as their median baseline EDSS score. Participants were 
  randomized to receive placebo or cladribine (a dosing 
cycle is 0.07 mg/kg/day SC for 5 consecutive days every 
4 weeks), for either 2 or 6 cycles followed by placebo for a 
  cumulative dose of 0.7 mg/kg or 2.1 mg/kg respectively.61 
The study included a 1-year, double-blind phase and a 6-year 
extension phase. During the 1-year phase, cladribine had no 
significant effects on progression of disability in patients with 
progressive MS.61 However, efficacy was demonstrated based 
on MRI parameters, as well as reduced relapse rates and 
disability progression among 229 patients with RRMS 
and progressive forms of MS who were treated in 3 trials 
conducted at the Scripps Research Institute.60 These patients 
received cumulative parenteral doses of cladribine, ranging 
from 0.7 mg/kg to 2.8 mg/kg administered over 4 to 6 months, 
using a monthly regimen of 5- to 7-day courses.60
Cladribine is now being developed as an oral formulation 
based on its oral bioavailability of 37% to 51%.62 Because 
the side effects of cladribine are generally dose dependent, 
development of oral cladribine is being pursued at doses 
that should give equivalent exposure to the lower doses 
used in the earlier parenteral studies (cumulative parenteral 
doses in the range of 0.7 mg/kg to 1.4 mg/kg).60,63,64 A phase 
III clinical trial of an oral formulation of cladribine, the 
  CLARITY (Cladribine Tablets in Treating MS Orally) 
trial, was recently completed.65,66 Based on this phase III 
trial, experience in the treatment of cancers, and the earlier 
parenteral studies, Merck Serono has submitted a New Drug 
Application for cladribine to the FDA for approval as a 
new therapy for treatment of RRMS.67 It may be one of the 
first of the emerging oral agents to reach the market. The 
CLARITY trial, a phase III, 96-week, randomized, double-
blind, placebo-controlled investigation (N = 1326) with oral 
cladribine (1 of 2 cumulative doses [3.5 mg/kg or 5.25 mg/kg] 
given in 2 or 4 short courses over the first 48 weeks with an 
additional 2 short courses starting at Week 48 and Week 52) 
reported reductions in ARRs by 58% (ARR 0.14; P  0.001) 
and 55% (ARR 0.15; P  0.001) in the cladribine low-dose 
and high-dose groups, respectively, compared with placebo 
(ARR 0.33). Secondary endpoints showed improvement 
in EDSS score and fewer T1 GdE lesions compared with 
placebo.65,66 With regard to safety issues, in the parenteral 
dosing MS trials involving cladribine, serious AEs (SAEs) 
similar to placebo were observed. However, there was a 
dose-related increase in infections, including 8 cases of 
herpes zoster, 1 case of Salmonella and 1 case of fatal, 
  fulminating, newly acquired hepatitis B that was thought not 
to be connected to the administration of cladribine.58,68 AEs 
in the CLARITY trial were similar to those reported in the Therapeutics and Clinical Risk Management 2010:6 163
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parenteral dosing studies. However, in addition, there were 
4 malignancies reported in the cladribine treatment groups 
(none in the placebo group) during the 96-week trial (1 case 
each of cervical, ovarian, and pancreatic cancer, as well as 
a case of malignant melanoma).49 A fifth case of cancer was 
reported in a woman who developed a choriocarcinoma when 
she became pregnant 6 months after study completion.49,69 
Dermatomal herpes zoster cases also occurred in 1.9% of 
patients. Although cladribine offers a distinct advantage 
as a convenient oral therapy, requiring as little as 2 cycles 
of 5 consecutive days each at the beginning of the first and 
second month of treatment for the first full year of therapy, 
the malignancies and infections appearing in the CLARITY 
trial coupled with the long-lasting effects of cladribine on 
the lymphocyte populations leave the assessment of risks 
involved with cladribine therapy unclear. The need for 
long-term monitoring is also an unresolved issue.
Alemtuzumab
Alemtuzumab was originally developed, and is approved, 
for  the  treatment  of  B-cell  CLL.  This  agent  is  a 
humanized monoclonal antibody that targets the CD52 
antigen, a cell surface glycoprotein that is present 
on 95% of T lymphocytes, B lymphocytes, monocytes, 
and eosinophils, as well as tissues of the male reproductive 
system.70,71 Binding of alemtuzumab to CD52 results in the 
rapid depletion of targeted cells by complement-dependent 
cytotoxic and antibody-dependent cellular cytotoxic 
  mechanisms.71 Prolonged lymphocyte depletion results 
from a single dose that lasts for years. For example, 
CD4+ T cells require a median period of 61 months to 
recover; CD8+ lymphocytes recover in approximately 
30 months (median recovery period); and monocytes and 
B lymphocytes return to baseline levels in 3 months.70 
Depletion of these cell types should  suppress the immune 
responses involved in the pathophysiology of MS, especially 
the early inflammatory events. Early studies of alemtuzumab 
in the treatment of secondary progressive MS (SPMS) sug-
gested efficacy in the treatment of relapses, however, not in 
the prevention of disability progression.72
The CAMMS223 study was a phase II, randomized trial 
with 334 treatment-naive patients with RRMS who were 
selected to receive either IFNβ-1a SC (44 µg 3 times per 
week) or annual intravenous (IV) cycles of alemtuzumab 
(12 mg or 24 mg per day for 5 consecutive days per year) 
for 36 months.73 The trial was designed to test the hypothesis 
that immunotherapy could influence long-term disability only 
if administered early in the disease course. Therefore, the 
eligibility criteria for this study limited the study to patients 
with an onset of symptoms of no more than 36 months and 
an EDSS score of 3 or less.73 Alemtuzumab significantly 
reduced the rate of sustained accumulation of disability (9.0% 
for alemtuzumab vs 26.2% for IFNβ-1a SC; P  0.001) and 
reduced the ARR (0.10 for alemtuzumab vs 0.36 for IFNβ-1a 
SC; P  0.001) compared with IFNβ-1a SC (Figure 5). 
Alemtuzumab also reduced MRI lesion burden; brain volume 
increased in the alemtuzumab group but decreased in the 
IFNβ-1a SC group.73 Four-year pooled data recently released 
demonstrated that ARRs were 0.10 (95% CI: 0.08, 0.12) for 
alemtuzumab and 0.33 (95% CI: 0.28, 0.41) for IFNβ-1a SC, 
representing a 72% risk reduction for relapse (P  0.0001) 
for alemtuzumab.74 The results apparently demonstrate the 
superiority of alemtuzumab with regard to efficacy compared 
with IFNβ-1a SC.73
There were SAEs during this trial, requiring the suspen-
sion of treatment with alemtuzumab after 3 patients devel-
oped immune thrombocytopenic purpura (ITP), one of whom 
died. The total number of patients with ITP included 1 patient 
receiving IFNβ-1a, and 6 patients receiving alemtuzumab.73 
  Autoimmune disorders, such as ITP, have occurred at a 
high rate with the treatment of MS with alemtuzumab.70,73 
These also include thyroid disorders (23% in the treatment 
group vs 3% in the placebo group in the CAMMS223 phase 
II trial) that occurred up to 30 months after the last dose 
of alemtuzumab was administered.73 Among the affected 
patients, 96% developed thyroid autoantibodies. Of the 
32 patients who developed hyperthyroidism, 3 experienced 
  serious hyperthyroid events (eg, Graves’ ophthalmopathy) and 
25 had sustained hyperthyroidism. Primary hypothyroidism 
developed in 10 patients, with 18 patients requiring long-term 
thyroid replacement therapy.73 In an earlier trial, Grave’s 
disease developed in 27% of patients, and 1 of 58 patients 
developed autoimmune hypothyroidism.70 Additionally, there 
was 1 case of renal failure due to Goodpasture’s syndrome 
that emerged 10 months after therapy.70 Aside from auto-
immune disorders, Coles et al70 reported the occurrence of 
opportunistic infections, including CMV and herpes. There 
were 3 cases of cancer reported during the CAMMS223 trial 
(non-Epstein-Barr virus-associated Burkitt’s lymphoma, 
breast cancer, and cervical cancer in ﾭsitu) among patients 
receiving alemtuzumab; 1 case of colon cancer was reported 
among patients receiving IFNβ-1a SC.73 The occurrence 
of acute cytokine release syndrome necessitates the use of 
high-dose steroids to ameliorate side effects during delivery 
of alemtuzumab doses. Serious infusion reactions developed 
in 1.4% of patients during the CAMMS223 trial.73Therapeutics and Clinical Risk Management 2010:6 164
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Based on current reports, risk-vs-benefit evaluations are 
difficult with alemtuzumab. The efficacy demonstrated in 
the CAMMS223 trial (superiority vs IFNβ-1a SC) suggests 
this may be one of the most potent agents available for use 
in treating MS (at least when dosed very early in the disease 
course). Although there may be very good efficacy when 
dosed early, there are major safety concerns, particularly 
those in association with autoimmunity, but also including 
opportunistic infections and malignancies. Many questions 
remain about the use of alemtuzumab, including how to use 
it over the long term. To date, alemtuzumab has been admin-
istered for 2 years (2 cycles). Experience from prior trials 
reveals that some safety issues have arisen years after the 
last dose was taken, yet no long-term data exist for this agent 
and the duration of effects of even a single 1-week cycle of 
alemtuzumab on the immune system is very long (5 years). 
Issues and questions that still need to be addressed include 
the need for additional doses; the number of doses that may 
be safely administered; the effects of prolonged depletion 
of CD4+ lymphocytes; and how to proceed in cases of sub-
optimal response. There are very significant risks associated 
with alemtuzumab and a great number of unknowns. Yet, to 
achieve maximum efficacy with this agent, it may be best to 
use it as early as possible in the disease course. Long-term, 
frequent monitoring probably will be necessary to ultimately 
define risk vs benefit.
Rituximab/ocrelizumab
Unlike several of the emerging agents that target T cells, 
rituximab and its humanized form, ocrelizumab, are 
  monoclonal antibodies that target B lymphocytes. Rituximab 
is approved in the United States for the treatment of non-
Hodgkin’s lymphoma and as a therapy for rheumatoid 
arthritis (RA) in combination with methotrexate in patients 
who have an inadequate response to one or more tumor 
necrosis factor antagonist therapies.75 Rituximab binds to 
the CD20 surface antigen on B lymphocytes, and directs 
the immune system to attack and kill the marked circulat-
ing CD20+ B lymphocytes. This depletion of B cells lasts 
more than 6 months.71,76 Affected cells include immature 
B cells, naive B cells, activated B cells, and memory 
B cells; however, stem cells, pro-B cells, and plasma cells 
are spared.77
Hauser et al78 conducted a double-blind, placebo-
controlled, phase II study of rituximab 1000 mg administered 
intravenously in 2 infusions 15 days apart. The primary 
endpoint for this trial was total number of GdE lesions at 
several time points over the 48-week study. Investigators 
found that compared with placebo, there was a decrease in the 
number of GdE lesions of 91% (P  0.001) and a decrease 
in new GdE lesions of 96% (P  0.001), suggesting that this 
agent causes a strong suppression of inflammation. Although 
not powered to demonstrate a difference in ARR, compared 
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Figure 5 Primary endpoints of the CAMMS223 trial – sustained disability and relapse. 
A) Kaplan–Meier curves for patients who reached the criteria for sustained accumulation of disability. B) Cumulative number of relapses. Reprinted with permission 
from CAMMS223 Trial Investigators, Coles AJ, Compston DA, et al. Alemtuzumab vs interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786–1801.73 
Copyright ® 2009 Massachusetts Medical Society.   All rights reserved.
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with placebo, the ARR was reduced by 56% (P = 0.04) at 
24 weeks and by 49% (P = 0.08) at 48 weeks.78
In this study, 50 of the 54 patients in the rituximab group 
(92.6%) reported “mild to moderate” infusion-associated 
AEs. More patients in the rituximab group (78.3%) than 
in the placebo group (40.0%) had infusion-associated AEs 
within 24 hours after the first infusion, and a total of 5.7% 
of patients in the placebo group and 4.3% of patients in the 
rituximab group withdrew from the study due to AEs.78 
Experience with rituximab in non-MS patients reveals that 
most acute AEs (fever, chills, rigors, and flu-like symptoms) 
are related to infusions.77 Additional less common AEs 
include nausea; pruritus; angioedema; asthenia; hypotension; 
acute respiratory distress syndrome; myocardial infarction; 
cardiogenic and anaphylactic shock; and mucocutaneous 
reactions.71,77 Tumor lysis syndrome, a rare and serious 
complication of rituximab infusion, has occurred in patients 
with cancer treated with high levels of rituximab.71 Rituximab 
contains a boxed warning for fatal infusion reactions, tumor 
lysis syndrome, severe mucocutaneous reactions, and the 
occurrence of PML.75 Carson et al79 reports that there are 
57 reported cases of PML after rituximab therapy in human 
immunodeficiency virus-negative patients. In general, these 
cases of PML are associated with the use of rituximab in 
patients receiving or having received other immunosup-
pressive therapies.79,77 Ocrelizumab, the humanized form of 
rituximab, is currently in development (phase II trials are 
underway), and the risks and benefits of this novel therapy 
remain an open question pending phase III trial results.
Other emerging agents
Fingolimod
Fingolimod (FTY720) is an oral, once-daily agent that was 
first pursued for use in transplantation patients; however, it 
was not found to offer any advantage over the standard of 
care, while having some increased risks, including macular 
edema.80 It is a prodrug that is phosphorylated in ﾭvivo to 
FTY720-phosphate (FTY720-P), which acts as an agonist 
of 4 out of 5 members of the sphingosine-1-phosphate (S1P) 
receptor family.81 Agonism of S1P receptor 1 on lymphocytes 
by FTY720-P leads to sequestration of lymphocytes in 
  secondary lymphoid tissues, such as lymph nodes and Peyer’s 
patches,81 lowering circulating lymphocytes by up to 85%.82 
Fingolimod, therefore, suppresses the immune response as 
T cells must migrate from the lymph nodes to the site of the 
pathogen or other foreign antigen to execute an immune 
response. Agonism of S1P receptors in the brain has been 
postulated to provide a mechanism by which fingolimod 
may be neuroprotective.83 Agonism of S1P receptor 3 by 
FTY720-P is the likely cause of bradycardia commonly 
observed with use of fingolimod.84
A phase II clinical trial of patients with RRMS revealed that 
fingolimod reduces GdE lesions, T2 lesions, and ARRs at daily 
doses of 1.25 mg (n = 83) and 5 mg (n = 77) compared with 
placebo (n = 81).85,86 ARRs were reduced by 55% (P = 0.009) 
and 53% (P = 0.01) compared with placebo with the 1.25-mg 
and 5-mg doses, respectively.85 Patients (N = 189) were treated 
for 24 months in an extension trial. They continued to exhibit 
a low level of disease activity with a high proportion (70%) 
of patients free of relapses (ARRs for Months 7 to 24: 0.12 to 
0.26), and with low levels of inflammatory activity on MRI 
(79% to 91% demonstrated no GdE lesions).86
Serious safety concerns, however, arose during the 
phase II clinical trial and extension. All patients receiving 
the 5-mg dose of fingolimod were switched to the 1.25-mg 
dose during the extension phase due to a less favorable 
safety profile at the higher dose.87 Kappos et al85 reported 
bradycardia (mostly with the initial dose), transient second-
degree Wenckebach atrioventricular block, and decreased 
pulmonary function (forced expiratory volume in 1 second 
[FEV1]).85,86 In addition, opportunistic infections and malig-
nancies (7 cases of skin cancer) were reported.87
TRANSFORMS (TRial Assessing injectable interferoN vs 
FTY720 Oral in RrMS), a 1-year, randomized, double-dummy, 
double-blind, parallel-group, phase III, active comparator 
investigation of fingolimod at 1.25 mg and 0.5 mg once daily 
with IFNβ-1a IM in patients with RRMS (n = 1292), was 
recently completed. The ARR was reduced by fingolimod to a 
range of 0.16 to 0.20 vs 0.33 by IFNβ-1a IM, correlating with 
a relative reduction of 38% to 52%.88 However, during this 
trial, there were 2 deaths from opportunistic infections (1 death 
from herpes encephalitis and 1 death from disseminated 
varicella infection). In addition, there were 8 skin cancers 
(including 3 malignant melanomas) and 4 breast cancer cases 
in the fingolimod groups vs 2 skin cancers in the IFNβ-1a IM 
group. Macular edema was also reported in 1% of FTY20-
treated patients.50 During TRANSFORMS, the safety profile 
of the 0.5-mg dose appeared to be better than the 1.25-mg 
dose, including lower rates of infection and bradycardia, 
but not of cancer.89 The occurrence of malignancies and 
opportunistic infections with fingolimod therapy is indicative 
of the potent immunosuppressive properties of this agent.
Two other phase III trials of fingolimod in MS include 
the placebo-controlled FREEDOMS (FTY720 Research 
Evaluating Effects of Daily Oral therapy in MS) and 
FREEDOMS II trial, which is underway. Results from the Therapeutics and Clinical Risk Management 2010:6 166
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2-year, phase III FREEDOMS study were recently reported: 
FTY720 reduced the relapse rate by 54% for the 0.5-mg 
dose and 60% for the 1.25-mg dose compared with placebo 
(P  0.001, respectively).90 In addition, FTY720 reduced the 
progression of disability over 2 years by 30% for patients on 
0.5 mg and 32% for those on 1.25 mg compared with placebo 
(P = 0.02, respectively).90 Both fingolimod doses were superior 
to placebo regarding MRI measures (P  0.001). The propor-
tions of patients in the 3 study groups who experienced AEs 
were similar at 93% to 94%.90 The majority of AEs were mild 
to moderate in all 3 treatment groups, however, the authors 
concluded that AEs may be less frequent with the 0.5-mg 
dose than with the 1.25-mg dose.90 AEs related to fingolimod 
and resulting in study discontinuation were most common in 
the 1.25-mg dose group, occurring in 14.2% of patients. AEs 
included bradycardia and atrioventricular heart block at the time 
of fingolimod initiation, as well as macular edema, elevated 
liver enzymes, and mild elevations in blood pressure.90 The 
most common serious AEs were bradycardia, MS relapse, and 
basal cell carcinoma. A total of 7 patients taking fingolimod and 
1 on placebo experienced bradycardia. Likewise, 7 patients in 
the fingolimod arms and 1 from the placebo arm experienced 
an MS relapse, whereas 5 patients in the treatment groups and 
3 in the placebo arm developed basal cell carcinoma.90
Any assessment of the risks versus the benefits for oral 
  fingolimod must consider the dose-related risks identified 
during the phase II and phase III trials. To reduce the 
  possibility of AEs, the high dose (5.0 mg) was eliminated 
during the extension trial,86 and lower doses have been pursued 
(0.5-mg and 1.25-mg doses) for the phase III investigations. 
The phase III TRANSFORMS study demonstrated clear 
superiority in efficacy of fingolimod over IFNβ-1a IM;88 
however, efficacy also may be dose dependent: reductions in 
the numbers of GdE lesions and T2 lesions during the phase 
II trial were substantially less at the 1.25-mg dose than at the 
5.0-mg dose,85 and the induction of lymphopenia has been 
shown to be dose dependent as well.82 Although patients 
and clinicians will be attracted to the convenience of an oral 
agent, this initial enthusiasm may be tempered by the need 
for extensive monitoring. For example, monitoring during the 
phase II fingolimod trial included serial pulmonary function 
testing, pulse rate monitoring for 6 hours after the first dose, 
and repeated ophthalmologic examinations.86
Teriflunomide
Like fingolimod, teriflunomide is an oral agent with once-daily 
dosing. Teriflunomide is the active metabolite of leflunomide, 
a pyrimidine synthesis inhibitor used in the treatment of 
RA. It appears that the therapeutic effects of teriflunomide 
are primarily associated with its inhibition of dihydro-orate 
dehydrogenase, which is a key cellular enzyme involved in de ﾭ
novo pyrimidine synthesis. Teriflunomide has a cytostatic effect 
on cells that rely on a de ﾭnovo pathway of pyrimidine synthesis 
rather than the salvage pathway, such as T and B lymphocytes, 
preventing their proliferation during an immune response. This 
appears to play a role in its therapeutic effect in MS.91
A phase II study has been conducted among 179 
patients with RRMS or SPMS to evaluate its safety 
and efficacy. The patients were randomized to receive 
  teriflunomide 7 mg/day, 14 mg/day, or placebo for 36 weeks. 
  Teriflunomide-treated patients had a significant reduction in 
T1- and T2-GdE-enhancing lesions with both doses of drug 
compared with placebo.92 Although teriflunomide is generally 
well tolerated, several SAEs were reported during this phase 
II trial, including hepatic dysfunction, rhabdomyolysis, 
  neutropenia/myelosuppression, and trigeminal neuralgia.92
In a second study, 116 patients being treated with an 
IFN were randomized to receive a daily dose of either 
  teriflunomide 7 mg (n = 37), teriflunomide 14 mg (n = 38), 
or placebo (n = 41), concurrently over 24 weeks. The objec-
tive of the study was to evaluate safety and efficacy of 
  teriflunomide as an add-on therapy to IFN-based DMTs. This 
study revealed that compared with placebo, the number of 
T1-GdE lesions was significantly reduced (7 mg, 56%; 14 mg, 
81%; all P  0.001) and the percentage of patients who were 
free of T1-GdE lesions was higher in both groups treated 
with teriflunomide (placebo, 58%; 7 mg, 70%; 14 mg, 82%). 
In addition, fewer relapses were reported among patients 
receiving the higher dose of teriflunomide (14 mg) vs placebo. 
However, each study group experienced treatment-emergent 
AEs, causing 1 patient in each group to discontinue participa-
tion in the trial. The proportion of patients with abnormal liver 
function tests (increased alanine transaminase) was higher in 
those receiving 14 mg (28.9%) versus those receiving 7 mg 
(13.5%), or among placebo patients (12.2%). The percentage 
of patients with AEs potentially associated with immunosup-
pression (including low white blood cell counts, infections, 
and infestations) was also higher in the teriflunomide-treated 
groups (placebo, 32%; 7 mg, 49%; 14 mg, 47%).93
Leflunomide, used for the treatment of RA, is rapidly 
and almost entirely converted to teriflunomide following 
oral ingestion.91 After a higher loading dose, the standard 
daily dose of leflunomide is 20 mg/day,94 while teriflunomide 
is being studied for use in MS at 7 and 14 mg/day.91 The 
  contraindications and warnings for leflunomide include a 
black box warning stating that it is contraindicated in pregnant Therapeutics and Clinical Risk Management 2010:6 167
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women or women of childbearing potential who are not using 
reliable contraception, and the label includes other warnings 
regarding its immunosuppressive potential (bone marrow sup-
pression), and rare but severe cases of liver injury.94 Warnings 
for teriflunomide will not be determined until its approval.
Laquinimod
Laquinimod is a once-daily oral immunomodulatory agent 
being developed by targeted drug modification of another 
compound, roquinimex. Roquinimex had shown promising 
efficacy in MS clinical trials, but its development was 
  discontinued in the late 1990s due to the occurrence of 
SAEs (myocardial infarction, pericarditis, and serositis).95–98 
  Laquinimod was derived from roquinimex by modifying 
the quinoline ring combined with chain elongation of the 
amidic methyl group, to create a new compound that is 
  pharmacologically and chemically distinct from its origins.98 
Sixty compounds with structural relationships to roquinimex 
were studied, and laquinimod was found to be more potent 
than roquinimex and to have a better safety profile.98,99 During 
development of laquinimod from roquinimex, activity in 
animal models was enhanced approximately 20-fold, while 
toxicity was decreased.98,99 The MOA of laquinimod is 
believed to be immunomodulatory, not immunosuppressive,98 
and to be associated with a Th1/Th2 shift and inhibition of the 
migration of inflammatory cells into the CNS. Suppressing 
Th1 cytokines while enhancing Th2 cytokines appears to 
reduce subsequent demyelination of nerve tissue in animal 
models.100
An initial double-blind, phase II study of laquinimod 
  randomized 209 patients with RRMS to receive 0.1 mg 
or 0.3 mg of laquinimod or placebo as oral therapy for 
24 weeks.101 GdE MRI scans of the brain were performed at 
baseline, every 8 weeks, and 8 weeks post-treatment. The 
investigators found that laquinimod 0.3 mg reduced the 
mean cumulative number of active lesions by 44% compared 
with placebo. The reduction was slightly greater, at 52%, 
in the subgroup of patients with at least 1 active lesion at 
baseline.101
A second double-blind, phase II study randomized 
306 patients with RRMS and at least 1 enhancing lesion 
at screening to receive 0.3 mg or 0.6 mg of laquinimod or 
placebo for 36 weeks.102 Monthly brain MRI scans, starting 
at Week 12, were performed during this trial. This was 
  followed by a 36-week extension, during which the patients 
originally treated with laquinimod continued laquinimod 
treatment at the original dose, and patients receiving 
  placebo were randomized to either the 0.3-mg or the 0.6-mg 
doses of laquinimod.103 Compared with placebo, treatment 
with laquinimod 0.6 mg demonstrated a 40% reduction 
(P = 0.0048) in the mean cumulative number of GdE lesions 
on the last 4 scans of the first 36-week study and a 51% 
reduction (P = 0.0001) in the mean cumulative number of 
GdE lesions on the last 7 scans.102
Although the trial was not powered to study relapse rates, 
there was a trend toward reduction with the 0.6-mg dose, 
with a 33% reduction (P = 0.09) in ARRs.102 Following the 
36-week, double-blind extension, an open-label extension was 
initiated. Results are now available for 155 of the 209 patients 
who entered the extension phase and are still undergoing 
treatment but have reached 24 months in the open-label phase. 
The mean ARR during the entire follow-up of 42 months for 
all patients was 0.46 compared with 0.53 in the period of 0 to 
18 months. The ARR was 0.45 for the original 0.6-mg laquin-
imod group, 0.50 for the original 0.3-mg laquinimod group, 
and 0.42 for the original placebo group. During the 24-month 
extension, 10.5% of patients entering the extension phase 
met confirmed disability progression on EDSS compared 
with 14.8% of laquinimod and placebo groups during the 
first 18 months. On MRI parameters, 61% of patients were 
free of GdE lesions at Month 42. Laquinimod continued to 
be safe and well tolerated, with the only side effects reported 
to be nasopharyngitis, back pain, and headache.104
Two phase III trials of laquinimod are currently under-
way, with recruitment complete: ALLEGRO (N∼1000), 
which will compare laquinimod with placebo and is 
  scheduled to be completed in November 2010; and BRAVO 
(N∼1200), which includes a treatment arm with IFNβ-1a IM 
and is scheduled to be completed late in 2011. In evaluat-
ing the risks versus benefits of laquinimod, two principal 
  questions remain to be resolved: 1) Will the clinical efficacy 
of laquinimod be robust? 2) Will laquinimod continue in its 
development without the appearance of the safety issues 
related to roquinimex (as it has thus far)?
Dimethyl fumarate (BG00012)
First introduced in the 1950’s, dimethyl fumarate has been in 
use as a treatment for psoriasis (an autoimmune skin disorder) 
in Europe for more than 30 years, although its formulation 
has evolved several times during that period. Dimethyl 
fumarate is administered 2 or 3 times daily. Its MOA is not 
clearly understood, although it is generally described as an 
  immunomodulator.105,106 More specifically, it may reduce the 
secretion of proinflammatory cytokines, inhibit the expression 
of adhesion molecules involved in the transmigration of 
immune cells into the CNS, and cause a Th1 to Th2 shift.106Therapeutics and Clinical Risk Management 2010:6 168
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A 12-month study of 10 psoriasis patients suggests that 
fumaric acid esters may have immunosuppressive activities as 
part of their MOA, as lymphocytes were decreased by about 
60%.107 In ﾭvitro studies by Treumer et al108 could provide 
an explanation of the MOA for this effect, as dimethyl 
fumarate was reported to be a potent inducer of apoptosis 
in human activated T cells. The effect of dimethyl fumarate 
on T cells has not been directly studied in patients with MS; 
however, lymphopenia was reported as an AE by Schimrigk 
et al109 in 3 of 10 patients with MS. Gold et al110 reported that 
  approximately 30% of patients with MS treated with dimethyl 
fumarate in the 24-week phase II trial had total white blood 
cell counts below the lower limit of the normal range.110
Dimethyl fumarate was studied in a phase II clinical trial, 
in which 257 patients with RRMS were randomized to receive 
either dimethyl fumarate 120 mg once daily, 120 mg 3 times 
daily, 240 mg 3 times daily, or placebo for 24 weeks.111 This 
was followed by a 24-week extension trial to assess safety. 
Patients taking placebo were switched during the extension 
phase of the trial to receive 240 mg of dimethyl fumarate 
3 times daily. Compared with placebo, the highest dose 
(240 mg 3 times daily [720 mg total]) resulted in a significant 
reduction (69%; P  0.0001) in the total number of new GdE 
lesions from Week 12 to 24. Lower doses, 120 mg once daily 
and 120 mg 3 times daily, did not cause a significant decrease 
in new GdE lesions, the primary endpoint of the study.109,111
Dimethyl fumarate is generally safe; however, AEs 
that relate to tolerability are common. These include 
  gastrointestinal effects (upper abdominal pain, nausea, 
  diarrhea) and flushing.109,111 In balancing the risks vs the 
benefits for this emerging therapy, efficacy was modest in 
the phase II trial and only significant with the highest dose. 
There are potentially significant tolerability and adher-
ence issues with the highest dose (requiring administration 
3 times a day). On the other hand, the long-term safety record 
  established from its use in psoriasis suggests that the risk side 
of the equation may not be limiting.
Summary
The risk-vs-benefit analysis of GA is being reshaped by the 
recent findings on GA that reflect its long-term safety and 
efficacy in MS, its use earlier in the disease, and the realiza-
tion of its greater efficacy than may have been perceived 
before the rigorous head-to-head trials. There is no evidence 
of NABs, which have reduced the effectiveness of all IFNβs. 
In an ever-evolving therapeutic landscape that will soon 
have several additional agents, the future role of GA in MS 
therapy will be dependent not only on the analysis of its own 
risks and benefits, but also on the analysis of the risks and 
benefits associated with the emerging therapies for MS. Like 
natalizumab, some of the emerging therapies are going to 
require the MS practitioner to consider new risks and to pay 
close attention to monitoring for potential AEs.
The risks and benefits of the emerging therapies vary 
widely. The therapies that are emerging from the fields of 
oncology and transplantation (cladribine, alemtuzumab, 
rituximab, and fingolimod) have been associated with, to 
various degrees, the risks associated with immunosup-
pressive therapies – serious opportunistic infections and/or 
malignancies. With alemtuzumab, the greatest risk appears to 
be the development of autoimmune syndromes. The effects 
of cladribine, alemtuzumab, and rituximab on the immune 
system are of a long duration that must be measured in years 
rather than in days or weeks. This makes the long-term risks 
associated with these treatments and how to use these treat-
ments over the long term of particular concern. Long-term 
monitoring will probably be mandatory. The efficacy of 
  alemtuzumab was clearly superior to that of IFNβ-1a SC 
in the CAMMS223 trial, and fingolimod was apparently 
  superior to IFNβ-1a IM in the TRANSFORMS study. 
Rituximab, fingolimod, and cladribine all have impressive 
positive MRI data. The risks and benefits of these emerging 
therapies will be difficult to assess even at the end of their 
phase III trials due to the lack of long-term data and the long 
duration of biological activity of these agents.
With laquinimod, dimethyl fumarate, and teriflunomide, the 
life-threatening risks associated with the emerging therapies dis-
cussed above have not occurred. At this point in their development, 
they appear to be safer. However, questions remain about how 
robust the efficacy of these therapies will be. The phase II trials 
were not designed and/or powered to show efficacy on the impor-
tant parameters of relapses and disability progression, and the risk-
vs-benefit analyses will be incomplete until the end of phase III 
trials. Although their MOAs are not well understood, laquinimod 
and dimethyl fumarate appear to be largely immunomodulatory, 
whereas teriflunomide, by preventing lymphocyte proliferation, 
is largely immunosuppressive. If these therapies do prove to be 
relatively safe and effective, because they are oral therapies, they 
may significantly impact the use of GA.
Looking toward the future, there will be many interest-
ing avenues to pursue in the treatment of MS as clinicians 
and their patients eagerly anticipate the approval of novel 
therapies that will be effective, convenient, and safe. Clearly, 
balancing the risks and benefits of selected therapies will 
become more challenging, and in the case of GA, more 
defined. Patients with MS, who are predominately young, Therapeutics and Clinical Risk Management 2010:6 169
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active women, will look toward practitioners to guide them 
in making the best management decisions possible to ensure 
the best outcomes, with a minimum of physical and cogni-
tive disability, and the most positive and improved quality 
of life possible.
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